Artiva Biotherapeutics (ARTV) Stock: Buy, Sell, or Hold?
ARTV - Artiva Biotherapeutics, Inc. Common Stock
$10.22
-0.20 (-1.92%)
▼
5d:
-8.13%
30d:
-11.36%
90d:
+27.75%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ARTV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ARTV shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ARTV shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ARTV is currently trading at $10.22, which is considered oversold relative to its 30-day fair value range of $10.89 to $11.72.
Technical Outlook: Technically, ARTV is in a uptrend. The price is currently testing key support at $10.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ARTV scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.80 (+250.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ARTV is in a uptrend. The price is currently testing key support at $10.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ARTV scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.80 (+250.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.89 -
$11.72
Company Quality Score
43/100
(HOLD)
Options IV Signal
30th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 30th percentile)
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 250.3% below Wall St target ($35.80)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.89 -
$11.72
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.59
(15.5%)
Support & Resistance Levels
Support Level
$10.10
Resistance Level
$11.80
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.92
Wall Street Target
$35.80
(+250.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 14, 2026 8:05 AM ET
Data refreshes hourly during market hours. Next update: 9:05 AM
Data refreshes hourly during market hours. Next update: 9:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARTV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
